help button home button Am J Pathol ASIP MEMBERSHIP
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Caccamo, A.
Right arrow Articles by LaFerla, F. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Caccamo, A.
Right arrow Articles by LaFerla, F. M.
(American Journal of Pathology. 2007;170:1669-1678.)
© 2007 American Society for Investigative Pathology
DOI: 10.2353/ajpath.2007.061178

Lithium Reduces Tau Phosphorylation but Not Aß or Working Memory Deficits in a Transgenic Model with Both Plaques and Tangles

Antonella Caccamo, Salvatore Oddo, Lana X. Tran and Frank M. LaFerla

From the Department of Neurobiology and Behavior, and Institute for Brain Aging and Dementia, University of California, Irvine, Irvine, California

Glycogen synthase kinase 3 (GSK-3) is a major kinase implicated in the pathogenesis of Alzheimer’s disease (AD), and reducing its activity may have therapeutic efficacy. Two variants exist, referred to as GSK-3{alpha} and GSK-3ß. In addition to the latter’s well-described role in the phosphorylation of tau, reports also suggest that GSK-3{alpha} may regulate amyloid precursor protein processing and Aß formation. The activities of both GSK-3{alpha} and GSK-3ß are reduced by lithium, a well-tolerated drug used in humans to combat bipolar disorder. Here, we investigate the therapeutic efficacy of chronic lithium administration in aged 3xTg-AD mice that harbor both plaques and tangles. We found that lithium reduced tau phosphorylation but did not significantly alter the Aß load. Despite the reduction in phosphotau, lithium treatment did not improve deficits in working memory. Although other studies have investigated the effects of lithium on tau biochemistry, this study represents the first to address comprehensively its therapeutic potential on other critical aspects of AD including its effect on Aß and learning and memory. It remains to be determined from human clinical trials whether lithium treatment alone will improve the clinical outcome in AD patients. These results, however, suggest that the most efficacious treatment will be combining lithium with other anti-Aß interventions.




This article has been cited by other articles:


Home page
 Therapeutic Advances in Neurological DisordersHome page
K. L. Lanctot, R. D. Rajaram, and N. Herrmann
Review: Therapy for Alzheimer's disease: how effective are current treatments?
Therapeutic Advances in Neurological Disorders, May 1, 2009; 2(3): 163 - 180.
[Abstract] [PDF]

Home page
 Arch Gen PsychiatryHome page
L. V. Kessing, L. Sondergard, J. L. Forman, and P. K. Andersen
Lithium Treatment and Risk of Dementia
Arch Gen Psychiatry, November 1, 2008; 65(11): 1331 - 1335.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Interv.Home page
J.-M. Beaulieu and M. G. Caron
Looking at Lithium: Molecular Moods and Complex Behaviour
Mol. Interv., October 1, 2008; 8(5): 230 - 241.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
X. Zhu, J. Avila, G. Perry, and M. A. Smith
Treating the Lesions, Not the Disease
Am. J. Pathol., May 1, 2007; 170(5): 1457 - 1459.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Society for Investigative Pathology.